Open Questions: Proteins

Ranked research questions extracted from wiki pages and knowledge gaps
Field: GenesProteinsMechanismsTherapeuticsDiseasesPathwaysCell TypesBrain RegionsMethods
Sort by: Importance Elo Potential Impact Tractability
200 questions found for field 'Proteins'
open ⚖ 1500
Coordinate regulation**: How is activity coupled to other spliceosomal steps?
📑 0.50 💥 0.50
open ⚖ 1500
Substrate recognition**: How does SNRNP200 select specific RNA substrates?
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism specificity**: How does SNRNP200 select specific substrates?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic optimization**: What is the optimal dosing and timing?
📑 0.50 💥 0.50
open ⚖ 1500
How does Gemin-6 dysfunction contribute to ALS and AD?
📑 0.50 💥 0.50
open ⚖ 1500
What is the precise structural role of Gemin-6 in the SMN complex?
📑 0.50 💥 0.50
open ⚖ 1500
Disease specificity
📑 0.50 💥 0.50
open ⚖ 1500
Gene Therapy
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type selective targeting
📑 0.50 💥 0.50
open ⚖ 1500
Structural studies
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic development
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Development:
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type resolution
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic Understanding
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic timing**: At what disease stage would TNN-targeted interventions be most effective?
📑 0.50 💥 0.50
open ⚖ 1500
What is the full extent of DLGAP3's role in neurodegenerative diseases?
📑 0.50 💥 0.50
open ⚖ 1500
Can oxidized KCNB1 burden be tracked in accessible biofluids as a progression biomarker?
📑 0.50 💥 0.50
open ⚖ 1500
Can deeper biophysical subclassification improve trial design for rare channelopathies?
📑 0.50 💥 0.50
open ⚖ 1500
What is the precise molecular mechanism of RAB3B in different vesicle pool regulations?
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic details**: How exactly does GTP hydrolysis drive scission?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting**: How can we specifically modulate dynamin-1?
📑 0.50 💥 0.50
open ⚖ 1500
Can patient-derived iPSC models define responder subgroups for Kv4/KChIP-modulatory therapies?
📑 0.50 💥 0.50
open ⚖ 1500
What are the optimal biomarkers for patient selection and response monitoring?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Window**: What is the optimal level of HDAC7 modulation for neuroprotection?
📑 0.50 💥 0.50
open ⚖ 1500
Small molecule inhibitors
📑 0.50 💥 0.50
open ⚖ 1500
How does CCM2 dysfunction interact with environmental factors?
📑 0.50 💥 0.50
open ⚖ 1500
Why are dopaminergic neurons selectively vulnerable to TMEM230 dysfunction?
📑 0.50 💥 0.50
open ⚖ 1500
Does NLRC5 expression change in AD or PD brain tissue?
📑 0.50 💥 0.50
open ⚖ 1500
Can NLRC5 modulation affect neuroinflammation in model systems?
📑 0.50 💥 0.50
open ⚖ 1500
How does NLRC5 interact with other NLR proteins in brain cells?
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies**: What therapeutic combinations will prove most effective?
📑 0.50 💥 0.50
open ⚖ 1500
Disease modification**: Can interventions begun early in disease course prevent progression?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development**: Can we identify robust biomarkers for patient stratification and treatment response?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window**: What level of protein reduction would be therapeutic without causing unacceptable side effects?
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism of mutation pathogenesis**: How do specific mutations impair UBQLN2 function, and do they also confer toxic gain-of-function?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic windows**: What is the therapeutic index of spliceosome modulators?
📑 0.50 💥 0.50
open ⚖ 1500
Cell type vulnerability**: Why are certain neurons more susceptible?
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches**: What other therapies synergize with GM-CSF modulation?
📑 0.50 💥 0.50
open ⚖ 1500
Temporal dynamics**: How does signaling change across disease stages?
📑 0.50 💥 0.50
open ⚖ 1500
Can the Gemin-6/7/8 subcomplex be directly targeted for therapeutic benefit?
📑 0.50 💥 0.50
open ⚖ 1500
Substrate recognition
📑 0.50 💥 0.50
open ⚖ 1500
Coordinate regulation
📑 0.50 💥 0.50
open ⚖ 1500
Small molecule modulators
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic target
📑 0.50 💥 0.50
open ⚖ 1500
Patient selection**: Which patients would benefit from RBM25-targeted therapy?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic target**: Is RBM25 a good drug target?
📑 0.50 💥 0.50
open ⚖ 1500
Regulation**: What controls RBM25 activity and localization?
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism**: How does RBM25 achieve specificity for different targets?
📑 0.50 💥 0.50
open ⚖ 1500
Can UPS enhancement rescue established pathology?
📑 0.50 💥 0.50
open ⚖ 1500
How does aging affect the ubiquitin system?
📑 0.50 💥 0.50
open ⚖ 1500
What determines whether aggregates are cleared by UPS vs. autophagy?
📑 0.50 💥 0.50
open ⚖ 1500
How does FIG4 deficiency cause specific neuronal vulnerability?
📑 0.50 💥 0.50
open ⚖ 1500
Can partial UPS enhancement be safely achieved in vivo?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window**: Can sufficient CNS penetration be achieved without immune suppression?
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity**: What are the cell-type-specific contributions of CTSL to neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
What is the relative contribution of NFE2L1 vs. Nrf2 in neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
Physiological functions**: What are the normal physiological roles of PEN2 beyond gamma-secretase?
📑 0.50 💥 0.50
open ⚖ 1500
Can cardiac channelopathy functional pipelines be adapted to CNS sodium-channel targets?
📑 0.50 💥 0.50
open ⚖ 1500
How should SCN5A variants be stratified for prospective mechanism-matched therapy?
📑 0.50 💥 0.50
open ⚖ 1500
Why are neurons specifically vulnerable to UPS dysfunction?
📑 0.50 💥 0.50
open ⚖ 1500
Personalized medicine
📑 0.50 💥 0.50
open ⚖ 1500
What is the optimal balance between Nrf2 activation and cellular homeostasis?
📑 0.50 💥 0.50
open ⚖ 1500
Why does the pathway become unresponsive in chronic neurodegenerative conditions?
📑 0.50 💥 0.50
open ⚖ 1500
Structural Studies
📑 0.50 💥 0.50
open ⚖ 1500
Gene Therapy
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Development:
📑 0.50 💥 0.50
open ⚖ 1500
Epigenetic Editing
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Microfluidics
📑 0.50 💥 0.50
open ⚖ 1500
Can spliceosome function be safely modulated therapeutically?
📑 0.50 💥 0.50
open ⚖ 1500
What is the full extent of PRPF6's substrate specificity?
📑 0.50 💥 0.50
open ⚖ 1500
Are there compensatory mechanisms that could be exploited?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic development
📑 0.50 💥 0.50
open ⚖ 1500
Structure-Function Studies
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism specificity
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Development
📑 0.50 💥 0.50
open ⚖ 1500
RNA-based therapeutics
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Cell type vulnerability
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic windows
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Translation
📑 0.50 💥 0.50
open ⚖ 1500
Small molecules
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Patient selection
📑 0.50 💥 0.50
open ⚖ 1500
Single-cell approaches
📑 0.50 💥 0.50
open ⚖ 1500
Spatial transcriptomics
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Protein engineering
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Fluid biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Imaging biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Functional biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Physiological functions
📑 0.50 💥 0.50
open ⚖ 1500
Allosteric vs. orthosteric
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy:
📑 0.50 💥 0.50
open ⚖ 1500
Complete Splicing Map
📑 0.50 💥 0.50
open ⚖ 1500
Structure-Function
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Development
📑 0.50 💥 0.50
open ⚖ 1500
Isoform-Specific Functions:
📑 0.50 💥 0.50
open ⚖ 1500
Cell-Type Specific Roles:
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Development:
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Studies:
📑 0.50 💥 0.50
open ⚖ 1500
Combination Therapies:
📑 0.50 💥 0.50
open ⚖ 1500
Isoform-Specific Functions:
📑 0.50 💥 0.50
open ⚖ 1500
Cell-Type Specific Roles:
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Development:
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Studies:
📑 0.50 💥 0.50
open ⚖ 1500
Combination Therapies
📑 0.50 💥 0.50
open ⚖ 1500
Structure-Function Studies:
📑 0.50 💥 0.50
open ⚖ 1500
Cell-Type Specific Functions:
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Development:
📑 0.50 💥 0.50
open ⚖ 1500
Structure-function studies
📑 0.50 💥 0.50
open ⚖ 1500
Biased ligand optimization
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Genetic studies
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Window
📑 0.50 💥 0.50
open ⚖ 1500
PROTAC Degraders
📑 0.50 💥 0.50
open ⚖ 1500
Direct PGC-1β agonists
📑 0.50 💥 0.50
open ⚖ 1500
Allosteric modulators
📑 0.50 💥 0.50
open ⚖ 1500
Protein-protein interaction inhibitors
📑 0.50 💥 0.50
open ⚖ 1500
Cell-Type Specificity
📑 0.50 💥 0.50
open ⚖ 1500
Disease Stage Effects
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specific functions
📑 0.50 💥 0.50
open ⚖ 1500
Temporal dynamics
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic optimization
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Biomarkers:
📑 0.50 💥 0.50
open ⚖ 1500
Brain-penetrant PDE inhibitors
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic understanding
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation
📑 0.50 💥 0.50
open ⚖ 1500
Clinical trial design
📑 0.50 💥 0.50
open ⚖ 1500
Disease modification
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Structural Studies:
📑 0.50 💥 0.50
open ⚖ 1500
Cell-Type Specific Functions:
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Development:
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism of iron regulation
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy timing
📑 0.50 💥 0.50
open ⚖ 1500
Disease stage effects
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Brain-Penetrant PHD Inhibitors
📑 0.50 💥 0.50
open ⚖ 1500
Cell-Type Specific Targeting
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Development
📑 0.50 💥 0.50
open ⚖ 1500
Combination Therapies
📑 0.50 💥 0.50
open ⚖ 1500
Disease-Modifying Approaches
📑 0.50 💥 0.50
open ⚖ 1500
Clinical Trial Design
📑 0.50 💥 0.50
open ⚖ 1500
Combination Approaches
📑 0.50 💥 0.50
open ⚖ 1500
Delivery systems
📑 0.50 💥 0.50
open ⚖ 1500
Saliva testing
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity
📑 0.50 💥 0.50
open ⚖ 1500
Normal function
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window
📑 0.50 💥 0.50
open ⚖ 1500
Epigenetic therapies
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Gene delivery
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity
📑 0.50 💥 0.50
open ⚖ 1500
Temporal regulation
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic index
📑 0.50 💥 0.50
open ⚖ 1500
p-tau217 + p-tau181
📑 0.50 💥 0.50
open ⚖ 1500
Biomarkers**: Can RBM25 splicing patterns serve as biomarkers?
📑 0.50 💥 0.50
open ⚖ 1500
Disease**: What are the precise disease mechanisms involving RBM25?
📑 0.50 💥 0.50
open ⚖ 1500
MS4A3 specific function**: What is the brain-specific role of MS4A3?
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism of action**: How do MS4A proteins modulate disease?
📑 0.50 💥 0.50
open ⚖ 1500
What determines TRA2B's tissue-specific splicing targets?
📑 0.50 💥 0.50
open ⚖ 1500
How do ALS mutations specifically affect motor neurons?
📑 0.50 💥 0.50
open ⚖ 1500
Can safe and effective splicing therapies be developed?
📑 0.50 💥 0.50
open ⚖ 1500
What is the precise role of CD45 in different disease stages?
📑 0.50 💥 0.50
open ⚖ 1500
What is the precise role of TRA2B in different disease stages?
📑 0.50 💥 0.50
open ⚖ 1500
Can CD45 modulation achieve therapeutic benefits safely?
📑 0.50 💥 0.50
open ⚖ 1500
Can TRA2B modulation achieve therapeutic benefits safely?
📑 0.50 💥 0.50
open ⚖ 1500
What are the optimal biomarkers for patient selection?
📑 0.50 💥 0.50
open ⚖ 1500
How does TRA2B interact with other RNA-binding proteins in disease?
📑 0.50 💥 0.50
open ⚖ 1500
Causal vs. correlational**: Does TNN dysregulation contribute to neurodegeneration, or is it a consequence?
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity**: Which neuronal and glial cell types produce TNN in the adult brain?
📑 0.50 💥 0.50
open ⚖ 1500
Receptor identification**: What are the primary neuronal receptors mediating TNN's effects?
📑 0.50 💥 0.50
open ⚖ 1500
Brain-specific function**: What is the precise role of hepsin in normal brain function?
📑 0.50 💥 0.50
open ⚖ 1500
AD mechanistic insights**: How does hepsin APP cleavage affect Aβ pathology?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting**: Can hepsin modulation provide therapeutic benefit?
📑 0.50 💥 0.50
open ⚖ 1500
Which p105 processing states in human brain best predict transition from adaptive to maladaptive neuroinflammation?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker utility**: Can hepsin serve as a diagnostic or progression marker?
📑 0.50 💥 0.50
open ⚖ 1500
Can microglia- or astrocyte-selective NF-kappaB modulation preserve host defense while reducing neurotoxicity?
📑 0.50 💥 0.50
open ⚖ 1500
How do p105-dependent transcriptional programs interact with amyloid and synuclein proteostasis pathways over disease stage?
📑 0.50 💥 0.50
open ⚖ 1500
What is the full extent of PPM1A substrate specificity in neurons?
📑 0.50 💥 0.50
open ⚖ 1500
What are the precise molecular mechanisms of DLGAP3 in LTP and LTD?
📑 0.50 💥 0.50
open ⚖ 1500
How is PPM1A activity regulated in the aging brain?
📑 0.50 💥 0.50
open ⚖ 1500
How do different disease mutations cause distinct phenotypes?
📑 0.50 💥 0.50
open ⚖ 1500
Can selective pharmacological modulation be achieved?
📑 0.50 💥 0.50
open ⚖ 1500
Can DLGAP3 modulation be safely achieved for therapeutic benefit?
📑 0.50 💥 0.50
open ⚖ 1500
Disease specificity**: Why do certain mutations cause retina-specific disease?
📑 0.50 💥 0.50

🌱 Cross-Pollination

Fields that illuminate Proteins through bridging wiki connections. See all cross-field connections →

Cross-pollination from Companies 508 bridges →
Cross-pollination from Institutions 740 bridges →
Cross-pollination from Genes 1,520 bridges →
Open Questions | Part of the SciDEX Atlas layer | API | Cross-field map